United Therapeutics Corporation
United Therapeutics Announces $1 Billion Share Repurchase Program
Summary
United Therapeutics Corporation announced on August 1, 2025, that it will repurchase up to $1 billion of its common stock under a share repurchase program authorized by its Board on July 30, 2025. The repurchase will be executed through two Accelerated Share Repurchase (ASR) agreements with Citibank, N.A., totaling $1 billion. The company will make an upfront payment of $1 billion on August 4, 2025, and will receive an initial delivery of shares on the same day, with final settlement expected in the fourth quarter of 2025 for the uncollared ASR and the first quarter of 2026 for the collared ASR. The company may be entitled to receive additional shares or, in certain circumstances, be required to make cash payment or deliver shares to Citibank at final settlement. This announcement reflects the company's confidence in its near-term prospects and balance sheet strength.
Profitelligence Alerts
Get alerts for UTHR
Be first to know when United Therapeutics Corporation files with the SEC.
Filing Categories
Exhibits (2)
Advertisement
About United Therapeutics Corporation
United Therapeutics Corporation is a biotechnology company engaged in the development and commercialization of innovative pharmaceutical products. Primarily focusing on therapies to address unmet medical needs for chronic and life-threatening conditions, United Therapeutics is notable for its contributions in the field of pulmonary arterial hypertension (PAH). The company offers a portfolio of products that include both oral and inhaled treatments, such as Remodulin and Tyvaso, providing critical care solutions that significantly improve patients' quality of life. Additionally, they are investing in innovative technologies such as organ manufacturing and regenerative medicine, showcasing a commitment to future medical advances. Headquartered in Silver Spring, Maryland, United Therapeutics operates across various stages of drug research, from clinical trials to post-market analysis. As a key player in the biotechnology industry, the company holds an influential position, contributing to significant advancements in therapeutic solutions and reinforcing its role in the healthcare market by addressing complex medical challenges and patient needs effectively.
Official SEC Documents
Advertisement